without the active substance. clinical trials

Adjustable brodalumab dosage regimen compared with standard brodalumab treatment for 52 weeks in subjects with moderate-to-severe plaque psoriasis and ≥120 kg body weight; ADJUST - Phase 4 – efficacy, A randomised, double-blind, controlled, parallel group, multi-centre trial

This study compares a flexible dose of Brodalumab, a psoriasis treatment, with its usual dose for people with moderate to severe plaque psoriasis who weigh 120 kg or more. It aims to see if the adjustable dose works better at clearing skin.